148 related articles for article (PubMed ID: 12121948)
1. Therapeutic efficacies of GW471552 and GW471558, two new azasordarin derivatives, against pneumocystosis in two immunosuppressed-rat models.
Jimenez E; MartÃnez A; Aliouat el M; Caballero J; Dei-Cas E; Gargallo-Viola D
Antimicrob Agents Chemother; 2002 Aug; 46(8):2648-50. PubMed ID: 12121948
[TBL] [Abstract][Full Text] [Related]
2. Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats.
Martinez A; Ferrer S; Santos I; Jimenez E; Sparrowe J; Regadera J; De Las Heras FG; Gargallo-Viola D
Antimicrob Agents Chemother; 2001 Dec; 45(12):3304-9. PubMed ID: 11709301
[TBL] [Abstract][Full Text] [Related]
3. [The experimental study of garlicin in treating Pneumocystis carinii pneumonia in rats].
Lu ZM; Tang HW; Zhang ZM; Liu JH; Zhang JS; Zhang WZ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2004 Dec; 22(6):357-60. PubMed ID: 15830863
[TBL] [Abstract][Full Text] [Related]
4. Activities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosis.
Martinez A; Aviles P; Jimenez E; Caballero J; Gargallo-Viola D
Antimicrob Agents Chemother; 2000 Dec; 44(12):3389-94. PubMed ID: 11083645
[TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats.
Aviles P; Aliouat EM; Martinez A; Dei-Cas E; Herreros E; Dujardin L; Gargallo-Viola D
Antimicrob Agents Chemother; 2000 May; 44(5):1284-90. PubMed ID: 10770763
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis carinii.
Walzer PD; Ashbaugh A; Collins M; Cushion MT
Antimicrob Agents Chemother; 2001 Nov; 45(11):3234-7. PubMed ID: 11600389
[TBL] [Abstract][Full Text] [Related]
7. Antifungal activities and cytotoxicity studies of six new azasordarins.
Herreros E; Almela MJ; Lozano S; Gomez de las Heras F; Gargallo-Viola D
Antimicrob Agents Chemother; 2001 Nov; 45(11):3132-9. PubMed ID: 11600368
[TBL] [Abstract][Full Text] [Related]
8. Establishment of rat model for Pneumocystis carinii infection and cloning of the surface glycoprotein A gene of Pneumocystis carinii.
Ouyang LS; Mo QY; Peng HJ; Chen XG; Shen SM
Di Yi Jun Yi Da Xue Xue Bao; 2002 May; 22(5):427-9. PubMed ID: 12390704
[TBL] [Abstract][Full Text] [Related]
9. Enhanced pneumocystis carinii activity of new primaquine analogues.
Goodwin TE; Boylan CJ; Current WL; Byrd JC; Edwards CB; Fuller DA; Green JL; Larocca CD; Raney KD; Ross AS; Tucker WA
Bioorg Med Chem Lett; 2000 Oct; 10(19):2205-8. PubMed ID: 11012030
[TBL] [Abstract][Full Text] [Related]
10. An experimental trial of artemether in treatment of Pneumocystis carinii in immunosuppressed rats.
Chen YT; Ma L; Mei Q; Tang Y; Liao XG
Chin Med J (Engl); 1994 Sep; 107(9):673-7. PubMed ID: 7805459
[TBL] [Abstract][Full Text] [Related]
11. Use of semiquantitative PCR to assess onset and treatment of Pneumocystis carinii infection in rat model.
O'Leary TJ; Tsai MM; Wright CF; Cushion MT
J Clin Microbiol; 1995 Mar; 33(3):718-24. PubMed ID: 7751383
[TBL] [Abstract][Full Text] [Related]
12. Iron chelators as therapeutic agents against Pneumocystis carinii.
Weinberg GA
Antimicrob Agents Chemother; 1994 May; 38(5):997-1003. PubMed ID: 8067783
[TBL] [Abstract][Full Text] [Related]
13. Search for extrapulmonary Pneumocystis carinii in an animal model.
Oz HS; Hughes WT; Vargas SL
J Parasitol; 1996 Apr; 82(2):357-9. PubMed ID: 8604119
[TBL] [Abstract][Full Text] [Related]
14. Detection of Pneumocystis carinii DNA by PCR amplification in various rat organs in experimental pneumocystosis.
Rabodonirina M; Wilmotte R; Dannaoui E; Persat F; Bayle G; Mojon M
J Med Microbiol; 1997 Aug; 46(8):665-8. PubMed ID: 9511814
[TBL] [Abstract][Full Text] [Related]
15. Fatal spontaneous pneumocystosis in nude rats.
Furuta T; Fujita M; Machii K; Kobayashi K; Kojima S; Ueda K
Lab Anim Sci; 1993 Dec; 43(6):551-6. PubMed ID: 8158979
[TBL] [Abstract][Full Text] [Related]
16. Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis.
Brun-Pascaud M; Chau F; Simonpoli AM; Girard PM; Derouin F; Pocidalo JJ
J Infect Dis; 1994 Sep; 170(3):653-8. PubMed ID: 8077724
[TBL] [Abstract][Full Text] [Related]
17. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat.
Schmatz DM; Powles MA; McFadden D; Nollstadt K; Bouffard FA; Dropinski JF; Liberator P; Andersen J
Antimicrob Agents Chemother; 1995 Jun; 39(6):1320-3. PubMed ID: 7574523
[TBL] [Abstract][Full Text] [Related]
18. Experimental evaluation of roxithromycin combined with dapsone or sulphamethoxazole on Pneumocystis carinii and Toxoplasma gondii dual infections in a rat model.
Brun-Pascaud M; Chau F; Derouin F; Girard PM
J Antimicrob Chemother; 1998 Mar; 41 Suppl B():57-62. PubMed ID: 9579714
[TBL] [Abstract][Full Text] [Related]
19. Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.
Brun-Pascaud M; Chau F; Garry L; Jacobus D; Derouin F; Girard PM
Antimicrob Agents Chemother; 1996 Sep; 40(9):2067-70. PubMed ID: 8878582
[TBL] [Abstract][Full Text] [Related]
20. Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo.
Walzer PD; Ashbaugh A; Collins M; Cushion MT
J Infect Dis; 2001 Nov; 184(10):1355-7. PubMed ID: 11679930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
